Patents are for the treatment of disorders associated with neuro-degenerative diseases
Suven Life Sciences (Suven) announced that the grant of one product patent from Israel (218525), one from Japan (5714729) and one from South Africa (2013/09100) corresponding to their new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), huntington’s disease, parkinson and schizophrenia.
With these new patents, Suven has a total of six granted patents from Israel, 17 granted patents from Japan and 20 granted patents from South Africa. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” says Venkat Jasti, Chief Executive Officer, Suven Life Sciences.
The company has 11 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, huntington’s disease, parkinson’s disease and obesity in addition to phase II ready developmental candidate SUVN-502 for and phase I candidate SUVN-G3031 for Alzheimer’s disease and Schizophrenia.
- Advertisement -
Comments are closed.